Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
An IO/TKI therapy showed a significantly improved PFS in the real-world setting compared to an IO/IO combination. In terms of OS, the improved treatment response of the IO/TKI group did not prevail.
Authors
- Maximilian Haack (ORCID: https://orcid.org/0000-0003-0957-2219)
- René Mager (ORCID: https://orcid.org/0000-0003-1286-0502)
- S. Neuberger
- Julie L. Boerner (ORCID: https://orcid.org/0000-0003-1711-4998)
- Gregor Duwe (ORCID: https://orcid.org/0000-0001-7008-1238)
- Stefanie Ziewers (ORCID: https://orcid.org/0000-0002-5301-5519)
- Axel Haferkamp
- Robert Dotzauer (ORCID: https://orcid.org/0000-0003-1532-4385)
Institutions
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1007/s12672-025-02131-z
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz